Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle
Introduction
Bovine viral diarrhea virus (BVDV) is a Pestivirus within the Flaviviridae family, and consists of two subtypes; a third subtype, BVDV-3, has been proposed [1]. Acute disease in BVDV-infected cattle is initially acknowledged based on fever, increased respiratory rate, diarrhea, and low white blood cell (WBC) counts [2]. BVDV-2 strains sometimes cause more acute infections than BVDV-1 with higher fever and severe diarrhea, as well as lower WBCs and platelets; this may result in death [3]. BVDV also is a major contributor to the bovine respiratory disease complex [4]. BVDV infections in pregnant cows may result in persistently infected calves, which may develop mucosal disease [3]. In the past few decades, adversely affected health and productivity of cattle have established BVDV as a virulent pathogen of high economic importance for the dairy and cattle industries [4].
BVDV is classified as a positive-sense single-stranded RNA virus. The virions contain a nucleocapsid surrounded by an envelope with glycoproteins ERNS, E1 and E2 [5], [6]. Among these glycoproteins, E2 is responsible for entry of the virus into the host cells [7], and is the major protective antigen, capable of inducing virus neutralizing (VN) antibodies and protection from BVDV challenge in cattle [8].
Since strong adjuvants are needed for optimal efficacy of subunit vaccines, we formulated the E2 protein with a combination adjuvant (TriAdj) consisting of a toll-like receptor-3 (TLR3) agonist, poly(I:C); an innate defense regulatory peptide, IDR-1002; and water-soluble polymer, poly[di(sodiumcarboxylatoethylphenoxy)]-phosphazene (PCEP). Poly(I:C) induces Th1-biased immune responses and promotes cross-presentation [9]. Immunomodulation by a synthetic IDR peptide can strengthen the host defense against microbial infections by recruiting activated immune cells [10], [11]. This cationic antimicrobial peptide also regulates innate immune responses at the site of infection or immunization by enhancing monocyte infiltration [12]. PCEP has immunostimulatory properties and induces balanced immune responses after co-administration with antigen [13].
Previously, E2 protein formulated with TriAdj (E2/TriAdj) was found to be protective in cattle when delivered intramuscularly (IM) [2]. However, intradermal (ID) vaccine delivery is of interest as epidermal and dermal layers of skin are rich in antigen-presenting cells (APCs) [14]. Therefore, vaccine delivery in these layers is expected to be as efficient, or even more, compared to delivery in muscle or subcutaneous tissue [15]. Furthermore, ID delivery avoids tissue damage to the muscle, which may lead to reduced meat quality and economic losses. In view of these advantages, the goal of this study was to develop an effective ID subunit BVDV-2 vaccine.
Section snippets
Vaccine, immunizations and challenge
A truncated, secreted version of the BVDV-2 E2 protein (strain Q140; accession number AAB01811; amino acids 41-383) was produced in a transient HEK293 cell expression system, and purified and characterized as described previously [2]. BVDV-seronegative seven to eight month-old Angus-Hereford cross-bred calves were randomly allocated to three treatment groups, designated IM, ID, and Placebo, with five animals per group. The calves were immunized IM or ID with a needle-free device, a Biojector®,
Humoral and cell-mediated immune responses elicited by E2 formulated with TriAdj
To determine the impact of delivery route on vaccine efficacy, calves were immunized with E2/TriAdj, either IM or ID, followed by challenge with BVDV-2. After vaccination a significant increase in IgG titers was observed in both the IM and ID groups when compared to the Placebo group (Fig. 1A). The titers were further enhanced after BVDV-2 challenge. However, there was no difference between the IgG titers of the IM and ID groups. The VN antibody titers specific for strain 1373 were also
Discussion
In this study, ID delivery of E2/TriAdj vaccine induced robust humoral and cell-mediated immune responses, as well as protection from BVDV-2 in cattle, equivalent to those induced by IM delivery. Moreover, infiltration of relevant immune cell populations including APCs were observed after ID delivery. This is the first report showing efficacy of ID delivery of an adjuvanted E2 protein subunit vaccine in a vaccination-challenge trial in cattle. These data support this route as very suitable and
Acknowledgements
We thank Elisa Martinez and Wayne Connor for assistance with the qRT-PCR, Sarah Mackenzie-Dyck for help with the cell isolations and Glenn Hamonic for training in cryo-sectioning the bovine skin tissues. We also thank Don Wilson, Brock Evans, and Sherry Tetland for care and handling of the calves. Financial support was provided by Saskatchewan Agricultural Development Fund (Grant number 20140232) and Alberta Livestock and Meat Agency (Grant number 2015B011R), Canada. This is manuscript 794 of
References (35)
- et al.
Phylogeny, classification and evolutionary insights into pestiviruses
Virology
(2009) - et al.
The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle
Vaccine.
(2014) The contribution of infections with bovine viral diarrhea viruses to bovine respiratory disease
Vet Clin North Am Food Anim Pract.
(2010)Molecular biology of bovine viral diarrhea virus and its interactions with the host
Veter Clin North Am Food Anim Pract.
(1995)- et al.
Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses
Vaccine.
(2005) - et al.
Anti-infective peptide IDR-1002 augments monocyte chemotaxis towards CCR5 chemokines
Biochem Biophys Res Commun.
(2015) - et al.
Intradermal vaccine delivery: will new delivery systems transform vaccine administration?
Vaccine.
(2008) - et al.
Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles
Vaccine.
(2012) - et al.
CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D
Vaccine.
(2002) - et al.
Co-existence of genetically and antigenically diverse bovine viral diarrhoea viruses in an endemic situation
Veter Microbiol.
(2008)
Control of bovine viral diarrhea infection by use of vaccination
Veter Clin North Am Food Anim Pract.
First finding of genetic and antigenic diversity in 1b-BVDV isolates from Argentina
Res Veter Sci.
The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies
Vaccine.
CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle
Vaccine.
Aluminium adjuvants–in retrospect and prospect
Vaccine.
Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination
Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV.
Veterinary medicine—a textbook of the diseases of cattle, horses, sheep, pigs and goats, 10th edition
Can Veter J.
Cited by (15)
Immunization with recombinant E<sup>rns</sup>-LTB fusion protein elicits protective immune responses against bovine viral diarrhea virus
2021, Veterinary MicrobiologyCitation Excerpt :We have recently found that the use of recombinant Erns-E2 protein vaccine formulated with MF59 and CPG-ODN could enhance cell immune responses against BVDV BJ175170 strain which is isolated from and prevalent in cattle from Beijing (China) (Wang et al., 2020). The protein vaccine-adjuvant combination could be as an alternative vaccination strategy to fight against BVDV, compared to commercial inactivated vaccine and attenuated vaccine (Sadat et al., 2017; Snider et al., 2014; Wang et al., 2020). So far, BVDV isolates are segregated into three different species, BVDV-1, BVDV-2, and BVDV-3 worldwide based on the difference of gene and antigen (Deng et al., 2015).
Evaluation of immunogenicity and protection mediated by Lawsonia intracellularis subunit vaccines
2021, Veterinary Immunology and ImmunopathologyCitation Excerpt :We formulated the first vaccine with an experimental combination adjuvant composed of host defense peptide 1002 (HDP), polyphosphazene (PZ) and a TLR agonist such as CpG oligodeoxynucleotides (ODN) or polyinosinic:polycytidylic acid (poly I:C) referred to as Triple Adjuvant (TriAdj). Together these adjuvants work together to elicit both cell-mediated and humoral immunity in livestock species (Garg et al., 2017, 2018; Kovacs-Nolan et al., 2009a, b; Kovacs-Nolan et al., 2009c; Prysliak and Perez-Casal, 2016; Sadat et al., 2017; Wilson et al., 2010). CpG ODN is a double-stranded (ds) DNA that binds to TLR9 and promotes NFκB activation and induction of Th1-type immune responses (Linghua et al., 2006; Mutwiri et al., 2009; Rasmussen et al., 2007; Tsujimura et al., 2004), while poly I:C is mimetic of viral dsRNA that binds to TLR3 and leads to increased expression of type I interferon and inflammatory cytokines, and stable Th1-type T cell immunity (Dragicevic et al., 2012; Matsumoto and Seya, 2008).
Polyphosphazene immunoadjuvants: Historical perspective and recent advances
2021, Journal of Controlled ReleaseCitation Excerpt :By far the most investigated polyphosphazene-based combination adjuvant is a ternary system, which includes IDR-1002 peptide, poly(I:C) and PCEP - “TriAdj”. Immunoadjuvant potency of TriAdj was validated in mice, rats, cotton rats, hamsters, rabbits, lambs, calves, and pigs with a variety of antigens using different administration routes, such as intramuscular, intranasal, and intrapulmonary [63,134,144–159]. Triadj was also investigated as part of the liposomal delivery system [160].
Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus
2020, VaccineCitation Excerpt :In FDA-approved vaccines, the limited adjuvants employed in vaccines for humans include aluminum salts, MF59, AS01, AS03, AS04, and CpG ODN [16]. We developed Triple Adjuvant (TriAdj), which consists of three components [17–19]: poly I:C, a ligand of the toll-like receptor-3 (TLR3); IDR-1002, an innate defense regulatory peptide; and poly [di (sodium carboxylatoethylphenoxy)] phosphazene (PCEP), a synthetic polymer. Formulation of TriAdj with human viral and bacterial antigens, including human respiratory syncytial virus (RSV) and Bordetella pertussis, induced efficient and long-lasting immune responses in animal models such as mice, sheep, and pigs [20–22].
Biodegradable Polyphosphazenes for Biomedical Applications
2023, Regenerative Engineering and Translational Medicine